



3 December 2024

Immupharma PLC
("Immupharma" or the "Company")

Appointment of Company Secretary

Immupharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm the appointment of Ashley Clarke ACA, as Company Secretary to the Company. The appointment is with immediate effect.

Ashley has been closely involved with the Company's accounts for several years via outsourced accountants, providing her with deep familiarity with Immupharma's operations. Now, as Group CFO, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure continued robust fiscal management. (More details on Ashley in 'Notes to Editors').

Ends

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information please contact:

Immupharma PLC (www.immupharma.co.uk)	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
 SPARK Advisory Partners Limited (NOMAD)	
Neil Baldwin	+44 (0) 203 368 3550
 Stanford Capital Partners (Joint Broker)	
Patrick Claridge, Bob Pountney	+44 (0) 20 3650 3650
 SI Capital (Joint Broker)	
Nick Emerson	+44 (0) 1483 413500

Notes to Editors

About Immupharma PLC

Immupharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a first-in class "immune tolerance restorer" for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases that share the same mechanism of action.

For additional information about Immupharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHC7VUS895.

Ashley Clarke ACA

Ashley has over a decade of experience in the financial sector, moving from a career in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley's experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

COSBSBDDDXGDGSD